Off-market insider buying with warrants at Resverlogix (RVX)

Off-market insider buying with warrants at Resverlogix (T:RVX)

Shenzhen Hepalink Pharmaceutical Co., a 10% Holder, acquired 1,333,333 Common Shares on a direct ownership basis at a price of $1.800 through a prospectus or prospectus exempt offering on June 20th, 2017. The insider also acquired 1,333,333 Warrants on a direct ownership basis with an exercise price of $2.050 for four fabulous years. This represents a $2,399,999 investment into the company's shares and an account share holdings change of 10.0%.

Resverlogix is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.